Review of cobalamin status and disorders of cobalamin metabolism in dogs

Stefanie Kather1 | Niels Grützner2,3 | Peter H. Kook4 | Franziska Dengler5 | Romy M. Heilmann1,3

1Department for Small Animals, Veterinary Teaching Hospital, College of Veterinary Medicine, University of Leipzig, Leipzig, Germany
2Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
3School of Veterinary Science, Massey University, Palmerston North, New Zealand
4Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
5Institute of Veterinary Physiology, College of Veterinary Medicine, University of Leipzig, Leipzig, Germany

Correspondence
Stefanie Kather, Small Animal Clinic, Veterinary Teaching Hospital, University of Leipzig, An den Tierkliniken 23, DE-04103 Leipzig, Germany.
Email: stefanie.kather@kleintierklinik.uni-leipzig.de

Abstract
Disorders of cobalamin (vitamin B12) metabolism are increasingly recognized in small animal medicine and have a variety of causes ranging from chronic gastrointestinal disease to hereditary defects in cobalamin metabolism. Measurement of serum cobalamin concentration, often in combination with serum folate concentration, is routinely performed as a diagnostic test in clinical practice. While the detection of hypocobalaminemia has therapeutic implications, interpretation of cobalamin status in dogs can be challenging. The aim of this review is to define hypocobalaminemia and cobalamin deficiency, normocobalaminemia, and hypercobalaminemia in dogs, describe known cobalamin deficiency states, breed predispositions in dogs, discuss the different biomarkers of importance for evaluating cobalamin status in dogs, and discuss the management of dogs with hypocobalaminemia.

KEYWORDS
cobalamin deficiency, cubam receptor, folate, homocysteine, hypercobalaminemia, hypocobalaminemia, methylmalonic acid, vitamin B12

1 | INTRODUCTION
Disorders of cobalamin (vitamin B12) metabolism are increasingly recognized in small animal medicine. Causes of cobalamin deficiency in dogs vary from chronic gastrointestinal (GI) disease to hereditary defects in cobalamin metabolism. Measurement of serum cobalamin concentration, often in combination with serum folate concentration, is routinely performed as a diagnostic test in small animal practice to detect dogs with vitamin B deficiency. The detection of hypocobalaminemia also has therapeutic implications. Because interpretation of the cobalamin status in dogs and the management of dogs with a suboptimal cobalamin status can be challenging, an update on this topic and a definition of the different cobalamin states in dogs are provided here.

The aim of this review is to critically evaluate the veterinary literature to define serum cobalamin status (normocobalaminemia, hypocobalaminemia and cobalamin deficiency, and hypercobalaminemia), describe causes of cobalamin deficiency states in dogs including breed predispositions, summarize breed-specific changes in cobalamin metabolism, discuss biomarkers of importance for evaluating cobalamin status in dogs, and discuss the treatment options for dogs in which a suboptimal or deficient cobalamin status has been diagnosed.

2 | COBALAMIN METABOLISM IN DOGS
2.1 | Ingestion and absorption of cobalamin
Cobalamin is a water-soluble vitamin, also referred to as vitamin B12. It is mainly ingested with food of animal origin with liver, kidney, meat,
egg, milk products as well as fish having high cobalamin content, but smaller amounts can also be produced by the intestinal microbiota.\(^1\)

Plants and plant products contain virtually no cobalamin and, whereas ruminants and other herbivores can produce a sufficient amount of cobalamin in their intestines, omnivorous or carnivorous animals including dogs and cats are not able to produce cobalamin. The intestinal microbiota of dogs and cats can produce cobalamin in the presence of cobalt, but because this site of cobalamin production is distal to the site of its absorption, this ability appears to be of little benefit to the animal. Most commercial pet foods, including vegan or vegetarian diets, are supplemented with cobalamin,\(^2,3\) but the content of dietary cobalamin varies between diets (dry diets: 0.05-0.25 mg/kg dry matter basis; canned diets: 0.03-0.59 mg/kg dry matter basis).\(^4\) The National Research Council (NRC 2006) recommendation for cobalamin fortification is 35 \(\mu\)g/kg dry matter for canine diets, regardless of the canine life stage.\(^5\) The concentration of serum cobalamin and cobalamin-dependent metabolites is not related to the dogs being fed a biologically appropriate raw food diet or a commercial dog food.\(^6\) Bound to dietary protein, cobalamin reaches the stomach where it is released by activated pepsinogen and gastric acid.\(^7\) Free cobalamin is then bound to haptocorrin (R protein, transcobalamin I) to protect it from bacterial utilization in the proximal GI tract.\(^7\) In the duodenum, pancreatic proteases separate cobalamin from haptocorrin, and free cobalamin is bound to intrinsic factor (IF). The major site of IF synthesis is the gastric mucosa in humans, whereas in dogs IF is produced primarily by the exocrine pancreas and to a lesser extent in the stomach.\(^6,9\) The cobalamin-IF-complex is then absorbed by receptor-mediated endocytosis. The receptor, known as cubam, is localized at the brush border of the ileum (Fig. 1A and 2). This receptor complex is comprised of 2 subunits, the proteins amnionless (AMN) and cubilin (CUBN) (Fig. 1A and 2).\(^10\) In addition to receptor-mediated cobalamin uptake at the ileal brush border epithelium, approximately 1% of dietary cobalamin is absorbed via passive diffusion across the intestinal mucosal epithelium, assumed to occur along the entire length of the GI tract.\(^11\) Within the lysosomes of the enterocytes, cobalamin is separated from IF and the receptor. Bound to another transport protein, transcobalamin, cobalamin is then transported within the bloodstream to its target tissues. In humans, 20%-30% of the cobalamin is bound to transcobalamin II, whereas most of the circulating cobalamin (70%-80%) is bound to transcobalamin I and thus unavailable for cellular uptake.\(^12,13\) Although transcobalamin II appears to be much more abundant in dogs than in humans, transcobalamin I exists in dogs.\(^14\) At the target tissue, cobalamin enters the cells through specific receptors and is then released from transcobalamin II (Fig. 1A).\(^12\) Approximately 15 \(\mu\)g/day of recirculating cobalamin is extracted by hepatocytes and secreted in bile bound to haptocorrin for enterohepatic recirculation.\(^15\) Within all eukaryotic cells, cobalamin acts as an essential cofactor for the intracellular enzymes methionine synthase and methylmalonyl-CoA mutase (Fig. 3).\(^16\)

**FIGURE 1** Schematic of the absorption of cobalamin by enterocytes in the distal small intestine (ileum). A, In the duodenum cobalamin is bound to intrinsic factor (IF). The cobalamin-IF complex is then absorbed by receptor-mediated endocytosis. This cubam receptor is localized at the brush border of the distal small intestine (ileum). The receptor complex is comprised of 2 subunits, the proteins amnionless (AMN) and cubilin (CUBN). Within the lysosomes of the enterocytes, cobalamin is separated from IF and the receptor. Bound to the transport protein transcobalamin II, cobalamin is then transported within the bloodstream to its target tissues. A small amount of circulating cobalamin is bound to transcobalamin I and thus unavailable for cellular uptake. Approximately 1% of dietary cobalamin is absorbed via passive diffusion across the intestinal mucosa. B, Various disorders can impair cobalamin metabolism.
2.2 | Intracellular function

2.2.1 | Methionine synthase

Methionine synthase, a cobalamin-, folate-, and pyridoxine (vitamin B6)-dependent enzyme, catalyzes the regeneration of methionine from homocysteine (HCY). This reaction links both cobalamin and folate metabolism (Fig. 3). Disorders associated with a deficiency in cellular cobalamin availability can thus lead to functional folate deficiency states and increased serum concentrations of HCY (hyperhomocysteinemia).

**FIGURE 2** Immunofluorescent staining of the cobalamin receptor subunits in the canine ileum epithelium. The expression of the cobalamin receptor was detected immunohistochemically in a cross section of an ileal villus from a dog using antibodies for the subunits (A) amnionless (AMN, green) and (B) cubilin (CUBN, green). Both subunits are localized throughout the entire enterocyte (cell membrane and cytosol). Nuclei are stained in blue with diamidine phenylindole (DAPI). The insert shows the corresponding secondary antibody control. Images were acquired using equipment at the Laser Scanning Microscopy Core Facility (College of Veterinary Medicine, University of Leipzig, Germany).

**FIGURE 3** Intracellular pathways of cobalamin metabolism. Methionine synthase catalyzes the regeneration of methionine from homocysteine. Disorders associated with a deficiency in cellular cobalamin availability thus can lead to functional folate deficiency and increased concentrations of homocysteine. Methylmalonic CoA mutase catalyzes the reaction from methylmalonyl CoA to succinyl CoA which is a key molecule in the tricarboxylic acid cycle. A lack of intracellular cobalamin leads to a reduced enzyme activity and an accumulation of methylmalonic acid (MMA). Excess MMA is excreted in the urine. MMA can also inhibit the activity of carbamoyl phosphate synthetase I, an enzyme of the urea cycle. Carbamoyl phosphate synthetase I normally metabolizes ammonia to carbamoyl phosphate. When this metabolic process is impaired, plasma ammonia concentration increases.
2.2.2 | Methylmalonyl-CoA mutase

Methylmalonyl-CoA mutase, a cobalamin-dependent enzyme, catalyzes the formation of succinyl-CoA from methylmalonyl-CoA, which is produced by the catabolism of odd-chain fatty acids and amino acids (Fig. 3). Succinyl-CoA is a key molecule in the citric acid cycle. A lack of intracellular cobalamin leads to a reduced enzyme activity and an accumulation of methylmalonic acid (MMA) intracellularly and subsequently also systemically (methylmalonic acidemia). On the one hand, excess MMA undergoes urinary excretion (methylmalonic aciduria); on the other hand, MMA can also inhibit the activity of carbamoyl phosphate synthetase I, an enzyme of the urea cycle. Carbamoyl phosphate synthetase I normally metabolizes ammonia to carbamoyl phosphate. When this metabolic process is impaired, plasma ammonia concentrations typically increase.1,17–20 Neurological disorders can thus be a complication of cobalamin deficiency states in dogs due to the increase in systemic MMA concentrations.1,17,18,21 In humans, neurological symptoms also occur in organic acidemias including methylmalonic acidemia.22

2.3 | Excretion of cobalamin

Body stores of cobalamin in dogs far exceed the amount of cobalamin that is normally lost through the intestinal tract. Cobalamin undergoes biliary excretion (bound to haptocorrin), and a large amount of cobalamin is conserved by enterohepatic recirculation.1

Renal glomerular filtration of the transcobalamin II-cobalamin complex is followed by tubular reabsorption to minimize urinary losses of cobalamin. Megalin, an endocytic receptor in the proximal renal tubulus that has a high affinity for the transcobalamin II-cobalamin complex, mediates renal reabsorption and retention of cobalamin. Free cobalamin is excreted in the urine.23,24 The cubam receptor is also present in the kidneys25 and is involved in the renal reabsorption of several proteins (eg, albumin, transferrin, and vitamin D-binding protein).

3 | LABORATORY TESTING TO EVALUATE COBALAMIN STATUS

Subnormal serum cobalamin concentration or cellular cobalamin deficiency in dogs can be detected by measuring serum cobalamin, HCY, and MMA concentrations. Although serum cobalamin concentrations are measured routinely in dogs and cats and determination of serum cobalamin is offered by a number of veterinary diagnostic laboratories, quantification of serum HCY and MMA is not routinely available, although both are considered as useful markers to determine the cellular cobalamin status of companion animals.7,26–28

3.1 | Laboratory tests

3.1.1 | Serum cobalamin concentration

There are several commercially available immunoassays for the measurement of serum cobalamin concentrations. An automated chemiluminescence assay is routinely used in North America and Europe, and the reference intervals (RI) for serum cobalamin concentrations in dogs that are used by the different veterinary diagnostic laboratories are similar (Table 1). An immunoassay is also available for measurement of serum cobalamin concentrations in dogs but yields different results than the chemiluminescent assay.29

The main indication for measuring serum cobalamin is to identify a subnormal cobalamin status.30 Because cobalamin-dependent metabolic reactions are localized to the intracellular compartment (ie, cytoplasm and mitochondria), the serum cobalamin concentration does not necessarily exactly reflect the whole-body cobalamin status in an individual dog. Intracellular storage of cobalamin is mostly as a cofactor bound to cobalamin-dependent enzymes that might or might not be saturated with cobalamin. Decreased liver and kidney cobalamin stores, and certain defects in cobalamin metabolism, such as malabsorption due a defect in the ileal receptor, can result in cobalamin deficiency. Therefore, other markers that more closely reflect the intracellular availability of cobalamin such as the serum concentration of HCY and MMA should ideally be included when assessing cobalamin status.31 Cobalamin is stable in serum even if samples are not strictly protected from light.32 Thus, in clinical practice, measurement of serum cobalamin can be conveniently performed in serum samples that are archived for up to 5 days. However, the long-term (>5 days) stability of cobalamin in serum samples has not been reported.

3.1.2 | Serum HCY concentration

Serum HCY concentrations can be measured by gas chromatography-mass spectrometry (GC/MS), with RIs of 5.0–22.1 μmol/L.27 and

| Laboratory test                       | RI for serum cobalamin concentration | Assay working range |
|---------------------------------------|--------------------------------------|---------------------|
|                                       | Lower reference limit | Upper reference limit | Lower limit of quantification |
| Texas A&M University Gastrointestinal Laboratory | 251 ng/L (185 pmol/L) | 908 ng/L (670 pmol/L) | 149 ng/L (110 pmol/L) |
| Idexx, Germany                        | 317 ng/L (234 pmol/L) | 1100 ng/L (812 pmol/L) | 45 ng/L (33 pmol/L) |
| Synlab, Germany                       | 299 ng/L (221 pmol/L) | 801 ng/L (591 pmol/L) | 150 ng/L (111 pmol/L) |
| Laboklin, Germany                     | 301 ng/L (222 pmol/L) | 802 ng/L (592 pmol/L) | 50 ng/L (37 pmol/L) |

Note: Shown are the RIs for serum cobalamin concentrations in dogs that have been established by 4 selected international veterinary diagnostic laboratories. The RIs used by these 4 diagnostic laboratories are comparable.
Methylmalonic acid concentrations can be determined in serum and urine samples. Serum MMA concentrations are measured routinely in human medicine by either a GC/MS or liquid chromatography-tandem mass spectrometry (LC/MS-MS) assay. However, measurement of serum MMA concentrations is currently not routinely performed in veterinary medicine. Serum MMA concentrations is easier determination because MMA concentrations are increased in some (12%) normocobalaminemic dogs. Serum MMA concentrations can also be increased with renal insufficiency or hypothyroidism.

In humans, HCY has direct toxic effects on neurons and endothelial cells, can induce DNA strand damage, oxidative stress, and apoptosis and also induce hepatic degeneration and fibrosis. Even small changes in serum HCY concentrations (≥5-10 μmol/L) increase the risk of cardiovascular diseases in people. Increased serum HCY concentrations occur in dogs with cardiac or renal disease.

Circulating HCY is mostly bound to albumin. As a consequence, diseases associated with hypoalbuminemia, such as protein-losing enteropathy (PLE), might be associated with a lower degree of hyperhomocysteinemia than expected or even with normohomocysteinemia. However, it is likely that breed-specific effects exist. For example in Greyhounds, and breed-specific RIs for serum MMA concentrations might need to be established because other breeds of dog could also fail to show an association between hypocobalaminemia and hyperhomocysteinemia. Preanalytical factors are also important because serum HCY concentrations can be falsely increased if the separation of red blood cells from serum is delayed.

### 3.1.3 | Serum MMA concentration

Methylmalonic acid concentrations can be determined in serum and urine samples. Serum MMA concentrations are measured routinely in human medicine by either a GC/MS or liquid chromatography-tandem mass spectrometry (LC/MS-MS) assay. However, measurement of serum MMA concentrations is currently not routinely performed in companion animals. RIs for serum MMA concentrations in dogs are 0.24-0.32 mmol/mol of creatinine and used for serum chemistry analysis can also be used for measurement of both cobalamin and MMA.

Because MMA production increases as a result of decreased intracellular availability of cobalamin, MMA is a useful marker of cobalamin deficiency at the cellular level. Such a deficiency can occur due to cobalamin malabsorption, deficient cobalamin transport (which is not reported in dogs), depletion of cobalamin stores in the liver and kidneys secondary to cobalamin malabsorption, or a combination of these, leading to insufficient amounts of cobalamin entering the cells. Tissues or cells with a high turnover rate such as enterocytes or blood cells are primarily affected. Dogs with a serum cobalamin concentration below RI have significantly higher serum MMA concentrations compared to dogs with normocobalaminemia, but serum MMA concentrations are increased in some compared to dogs with normocobalaminemia. In cobalamin-deficient Shar-Pei, where a suspected hereditary but late-onset form of cobalamin deficiency with mostly signs of GI disease exists, serum MMA concentrations can even be 10 times higher than in cobalamin-deficient dogs of other breeds.

Careful interpretation of serum MMA concentrations should be exercised in the presence of other conditions that can affect serum MMA concentrations, such as renal insufficiency causing increased serum MMA concentrations. Therefore, serum concentrations of creatinine, symmetric dimethylarginine, or both should also be evaluated when interpreting serum MMA concentrations. Other possible causes for increased serum MMA concentrations, unrelated to primary cobalamin deficiency and renal disease, are dehydration, small intestinal (SI) dysbiosis and inherited defects of the enzyme systems involved in the metabolism of cobalamin and MMA. Inherited etiologies also include defects in the absorption and transport of cobalamin such as a deficiency of transcobalamin II. Such defects have been reported in people, but further studies are needed to investigate whether dogs are also affected by these.

Of healthy normocobalaminemic Border Collies, 38% have increased urine MMA concentrations. None of these dogs have increased serum HCY or decreased cobalamin concentrations compared to cobalamin-deficient dogs. These cobalamin-deficient Border Collies have a primary methylmalonic aciduria. However, bacterial contamination of urine also has to be considered as a cause for increased urinary MMA concentrations. A similar presentation occurs in children with a defect in the methylmalonyl-CoA mutase.

### 3.2 | Interpretation of cobalamin status

The currently recommended interpretation of the cobalamin status in dogs is summarized in Table 2 (the cutoff serum cobalamin
concentrations proposed below are based on the assay offered through the Gastrointestinal laboratory at Texas A&M University and Fig. 4.

3.2.1 | Normocobalaminemia
Normocobalaminemia refers to a serum cobalamin concentration within the RI for healthy dogs. However, serum cobalamin concentration does not accurately reflect the cobalamin status on the cellular level. If cobalamin transport into the cell is hindered, intracellular cobalamin deficiency might result while the cobalamin concentration in serum remains within normal limits. In human medicine, standard assessment of cobalamin status includes measurement of serum cobalamin, HCY, MMA, and holotranscobalamin. Holotranscobalamin is the biologically active fraction of cobalamin that is bound to transcobalamin II. A canine holotranscobalamin assay is currently not available; therefore, measurement of serum MMA and HCY in addition to serum cobalamin is recommended (but currently not widely available) to assess cobalamin status in dogs.

Twelve percent of dogs with chronic enteropathy and a serum cobalamin concentration within the normal RI have an increased serum MMA concentration. Twenty-two percent of dogs with cobalamin close to the lower end of the RI have increased serum MMA concentrations. These data suggest that a subtle or mild subclinical intracellular cobalamin deficiency exists in these dogs. In humans with suboptimal cobalamin status, the response to cobalamin supplementation is a marked reduction in serum MMA concentration. Dogs with serum cobalamin concentrations at the lower end of the RI have a normalization of serum MMA concentrations after cobalamin supplementation. This could indicate that the discrepancy between an increased serum MMA and a normal cobalamin concentration reflects intracellular cobalamin deficiency despite that body stores of cobalamin are sufficient to maintain normocobalaminemia.

Such a “cobalamin resistance” occurs in geriatric, diabetic, and hemodialysis human patients. Alternative explanations could be the shift to an increased pool of circulating cobalamin with hepatic disease or a compromised translocation of cobalamin to the intracellular space (which is not reported in dogs).

3.2.2 | Hypocobalaminemia
Hypocobalaminemia is typically referred to in dogs with a serum cobalamin concentration between the lower limit of quantification (LoQ) of the assay and the lower reference limit. Dogs with cobalamin deficiency have an undetectable serum cobalamin concentration (ie, below LoQ) and a serum MMA concentration above RI. Cobalamin should be supplemented whenever serum cobalamin concentration is suboptimal (ie, less than approximately 400 ng/L).

Hypocobalaminemia is typically referred to as a serum cobalamin concentration between the lower limit of quantification (LoQ) of the assay and the lower reference limit. Dogs with cobalamin deficiency have an undetectable serum cobalamin concentration (ie, below LoQ) and a serum MMA concentration above RI. Cobalamin should be supplemented whenever serum cobalamin concentration is suboptimal (ie, less than approximately 400 ng/L).
possible that other factors (such as acute secondary SI dysbiosis due to
an acute flare of the underlying enteropathy, proton-pump inhibitor
use,25 or administration of oral antibiotics—Manchester AC, Blake A,
Webb C, Lidury C, Steiner J, Suchodolski J. Tylosin causes dysbiosis
associated with altered fecal unconjugated bile acids in healthy dogs.
Proceedings of the ACVIM Forum 2019. GI11 [abstract]56 contrib-
uted to the suboptimal serum cobalamin, but normal serum MMA
concentrations in the remaining 69% of dogs and that the
hypocobalaminemia in these dogs did not reflect a true whole-body
cobalamin deficiency. However, it remains to be determined whether
the hypocobalaminemia associated with SI dysbiosis correlates with
cobalamin deficiency at the cellular level.

After supplementation, cobalamin is rapidly extracted from plasma
by tissues where it binds to cobalamin-dependent enzymes with a rel-
atively long half-life.58 Thus, it is possible that the half-life of cobala-
min that is bound intracellularly as a coenzyme exceeds the residence
time of cobalamin within the circulation, which would mean that
cobalamin continues to be active in the tissues and cobalamin-
dependent metabolic processes are able to occur despite low serum
cobalamin concentrations. This is often observed in the treatment of
dogs with inherited disorders of cobalamin metabolism.59

3.2.3 Cobalamin deficiency

The term cobalamin deficiency is not well-defined in the veterinary lit-
erature. Most current cobalamin assays have an LoQ between 45 and
150 ng/L (Table 1). We propose using the term cobalamin deficiency
for dogs with an undetectable serum cobalamin concentration and a
serum MMA concentration above RI (Table 2, Figure 4).

Sixty-three percent of dogs with undetectable serum cobalamin
concentrations have increased serum MMA concentrations indicating
acellular cobalamin deficiency.26 Normal serum MMA concentrations
in the remaining 37% of dogs with an undetectable serum cobalamin
concentration might suggest that a sufficient amount of cobalamin as
a cofactor is bound to cobalamin-dependent enzymes and a normal
activity of these enzymes is maintained in these dogs, whereas cobala-
min concentrations in the circulation are already severely decreased
because of their much shorter half-life.58 Therefore, measurement of
serum cobalamin concentration alone is not sufficient to diagnose or
exclude intracellular cobalamin deficiency, and determination of
serum MMA (and HCY) is recommended in addition to serum cobala-
min concentration.

3.2.4 Hypercobalaminemia

Hypercobalaminemia refers to a serum cobalamin concentration
above the normal RI. Until recently, hypercobalaminemia was consid-
ered as a benign finding and was basically ignored in companion ani-
mals. However, recent data in people suggest that
hypercobalaminemia is an underestimated finding that can reflect a
number of serious underlying diseases such as solid neoplasms, hema-
tological and other malignancies, and hepatic or renal diseases.60-62
Abnormally high serum cobalamin concentrations occur in cats with
hepatic and neoplastic diseases.63 A retrospective analysis of the
medical records and data from 592 dogs that were presented for fur-
ther diagnostic workup at the University of Leipzig Small Animal Clinic
showed that 2% (n = 11) of all dogs in which serum cobalamin status
was determined and that did not receive any supplemental cobalamin
(n=487 dogs) had a serum cobalamin concentration above RI, ranging
from 1,100-3,561 ng/L (median: 1,334 ng/L) (unpublished data). These
hypercobalaminemic dogs had mostly (73%) signs of chronic GI
disease, and a neoplastic condition could not be definitively excluded
in 82% of the dogs. These findings suggest that hypercobalaminemia
is less frequently observed in dogs than in cats,63 in which a preva-
lence of 14% (28 of 202 cats) was observed in the study above
(unpublished data), and that hypercobalaminemia might be of clinical
relevance in dogs that have not received supplemental cobalamin. A
higher prevalence (36%) of hypercobalaminemia is reported
(Bertolani C, Tabar MD, Espanza A, et al. Hypercobalaminemia in
144 samples from cats and dogs. J Vet Intern Med. 2019;33
(2):1070-1071 [abstract]) in a smaller number of dogs with clinical
signs similar to those reported above (unpublished data), the upper
reference limit in which was also much lower (590 ng/L) which might
at least in part explain the discrepancy between the reported preva-
ience of hypercobalaminemia in dogs. Measurement of serum cobala-
im concentrations at 2 different laboratories also needs to be
considered when comparing the prevalence of hypercobalaminemia
between these 2 studies. Serum MMA concentrations have not been
evaluated in dogs with hypercobalaminemia.

4 CONDITIONS ASSOCIATED WITH A
SUBOPTIMAL COBALAMIN STATUS

Hypocobalaminemia and cobalamin deficiency can have a variety of
causes in dogs including exocrine pancreatic insufficiency (EPI),
chronic severe ileal disease (eg, infiltrative disorders such as idiopathic
inflammatory bowel disease [IBD], alimentary lymphoma, or GI histo-
plasmosis). SI dysbiosis (though this condition is rarely definitively
diagnosed as the acquisition and analysis of the SI microbiota is cum-
bersome and invasive), and inherited conditions (Fig. 1B).49,64-71
Hypocobalaminemia also occurs in people with IBD (Crohn’s disease
and ulcerative colitis). There are no reported cases of cobalamin defi-
ciency of dietary origin in dogs.31

4.1 Clinicopathological findings and clinical
presentation

Blood cell count abnormalities, typically nonregenerative anemia with
megaloblastosis, neutropenia, and hypersegmented neutrophils, can
be early signs of derangements in cobalamin metabolism.72 With pro-
gression, disorders of phospholipid and amino acid metabolism have
been documented in other species and might also occur in dogs.21,73

In addition to blood cell dyscrasias and organic acidaemias associ-
ated with neurological signs, especially dogs with hereditary cobala-
im deficiency can show severe clinical signs such as failure to thrive,
anorexia, lethargy, vomiting, and diarrhea. The age of affected dogs at presentation with clinically apparent disease also varies, with the majority of dogs showing clinical signs early in life and a smaller proportion of dogs having a more delayed onset of clinical signs.

### 4.2 | Hereditary conditions

A genetic background for cobalamin deficiency has been confirmed or suspected in Giant Schnauzers,\(^1\)\(^\pm\)\(^4\) Border Collies,\(^1\)\(^8\)\(^,\)\(^7\)\(^5\)\(^-\)\(^7\) Chinese Shar-Peis,\(^7\)\(^9\) Beagle dogs,\(^1\)\(^7\)\(^9\)\(^,\)\(^8\)\(^1\)\(^-\)\(^8\)\(^3\) Australian Shepherd dogs,\(^1\)\(^9\)\(^,\)\(^2\)\(^5\) a Yorkshire Terrier,\(^2\)\(^0\) and also a mixed breed dog (Maguire D, Solano-Gallego L, English K, et al. Cobalamin deficiency in a collie cross Bedlington Terrier. Available at: https://www.esvcp.org/index.php/docman/clin-path-cases/106-case-2-maguire-with-diagnosis/file.html); genetic defects and hypocobalaminemia has been confirmed for a few canine breeds. Certain dog breeds have a predisposition for hypocobalaminemia for which the underlying mechanism or cause has not been elucidated (see Section 4.2.1.). In some of these breeds, cobalamin deficiency is a genetic trait. This condition is classified as a hereditary or selective disorder in cobalamin metabolism (see Section 4.2.2.). Finally, a genetic cause (eg, a specific mutation of the cubam receptor) of selective cobalamin malabsorption was identified or confirmed in some affected dog breeds (see Section 4.2.3). The current literature is reviewed here, but it should be noted that additional dog breeds might have a predisposition for cobalamin deficiency because current studies do not cover an exhaustive list of geographical areas.

#### 4.2.1 | Breed predispositions for hypocobalaminemia and cobalamin deficiency

Serum concentrations of cobalamin have been used for many years in veterinary practice to identify dogs with hypocobalaminemia or cobalamin deficiency, and 2 large surveys have been conducted with the aim to identify canine breeds that might have a predisposition to develop cobalamin deficiency.\(^7\)\(^0\)\(^,\)\(^8\)\(^4\) Test results of serum samples from 9,960 dogs submitted over a 13-year period to a laboratory in the United Kingdom were analyzed to determine breed predispositions for hypocobalaminemia, hypofolatemia, or both.\(^8\)\(^4\) Breeds of dogs with an increased frequency of hypocobalaminemia were the Chinese Shar-Pei, Staffordshire Bull Terrier, German Shepherd Dog, and mixed breed dogs. Golden Retrievers had a decreased odds ratio for being diagnosed with hypocobalaminemia. There is an increased frequency of hypocobalaminemia in Chinese Shar-Peis and German Shepherd Dogs in North America.\(^7\)\(^0\) A high prevalence of severe hypocobalaminemia in Stafford Bull Terriers and mixed breed dogs is reported in the United Kingdom,\(^8\)\(^4\) but Staffordshire Bull Terriers do not have an increased risk of hypocobalaminemia in the United States.\(^7\)\(^0\)

In the North American study,\(^7\)\(^0\) serum cobalamin test results from 28,675 dogs of 164 breeds were reviewed to identify breeds with an increased risk of being identified with hypocobalaminemia. This study found Greyhounds to have the highest proportion of serum samples submitted for cobalamin analysis and also the lowest serum cobalamin concentrations compared to the other 18 breeds of dogs that were significantly more likely to have a subnormal serum cobalamin concentration. This suggests that hypocobalaminemia or cobalamin deficiency occurs frequently in this breed, which is supported by another study indicating that Greyhounds frequently have hyperfolinemia with or without hypocobalaminemia.\(^3\)\(^8\) The high percentage of affected dogs with hyperhomocysteinemia in this study suggests that cobalamin deficiency is common in this breed.\(^3\)\(^8\) However, it is also possible that normal serum cobalamin concentrations in Greyhounds are lower than in dogs of other breeds, thus calling for a breed-specific RI. An effect of exercise is unlikely because Greyhounds included in the study were all retired racing dogs.\(^3\)\(^8\)

#### 4.2.2 | Selective cobalamin malabsorption

Selective cobalamin malabsorption is a rare congenital disease. The first report about selective cobalamin malabsorption in dogs describes 2 related Giant Schnauzers that lacked the expression of the cobalamin-IF-receptor complex in the apical brush border of the ileal epithelium.\(^1\) The human analog of this rare genetic disorder is called Imerslund-Gräsbeck syndrome (IGS). Dogs with IGS are unable to absorb dietary cobalamin.\(^1\)\(^,\)\(^1\)\(^7\)\(^4\)

Classical clinical signs of IGS such as intermittent diarrhea, inappetence, poor body condition, and failure to grow typically manifest within the first year of age. Around that time fetal stores of cobalamin are depleted while growth demands cobalamin to be utilized at high rates. Dogs might be misdiagnosed because of the secondary effects of hypocobalaminemia on metabolism such as the development of hypoglycemia, ketoacidosis, and hyperammonemia.\(^1\)\(^8\)\(^,\)\(^9\)\(^,\)\(^7\)\(^8\) Therefore, cobalamin deficiency should be considered as a differential diagnosis in dogs presented with a suspicion of a portosystemic shunt, hydrocephalus, or metabolic disorders such as hypoglycemia and renal insufficiency.\(^1\)\(^7\)

Another possible clinical manifestation of IGS is intermittent impaired swallowing.\(^7\)\(^6\) Mucosal ulcers might also develop,\(^7\)\(^6\)\(^,\)\(^8\) but glossitis, glossodynia, and stomatodynia are reported only in people with cobalamin deficiency. Additionally, bradyarrhythmia is a possible clinical sign in dogs.\(^7\)\(^6\) Skin lesions (reversible hyperpigmentation) occur in children with IGS.\(^8\)\(^6\)

Hematologic abnormalities in human patients with IGS include a dyserythropoiesis that is typically characterized by a nonregenerative anemia of varying severity and neutropenia. Microscopically, hypersegmented neutrophils may be noted. Megaloblastosis is rarely seen in dogs,\(^7\)\(^5\) and some dogs with IGS present with a normal hemogram.\(^7\)\(^6\) Although children with this disorder develop macrocytic anemia, the anemia in dogs is usually normocytic and normochromic.\(^7\)\(^2\)\(^,\)\(^8\)\(^7\)\(^-\)\(^8\)\(^9\) Thus, megaloblastic anemia does not appear to be as closely associated with cobalamin deficiency in dogs as it is in people. In affected dogs, both large and small red blood cells are present systemically, resulting in an increased red cell distribution width while the mean cellular volume remains within RI.\(^7\)\(^2\) Rarely, dogs with IGS can present with Heinz body anemia caused by hyperhomocysteinemia.\(^7\)\(^8\)
Breed-specific changes in serum cobalamin concentrations and distinct clinical manifestations exist in the Border Collie, Beagle, and Chinese Shar-Pei breeds (Table S1).

**Border Collie**

Several case reports and case series have described a selective cobalamin malabsorption in the Border Collie breed. Clinical manifestations in some cases are mild and the onset of clinical signs can be delayed into early adulthood compared to other breeds with selective cobalamin malabsorption. Also, juvenile cobalamin deficiency might not be routinely associated with hematologic changes in the Border Collie breed.

About 40% of healthy Border Collies have increased urine MMA levels, but none of the normocobalaminemic dogs in that study had increased plasma HCY concentrations compared to the Border Collies with cobalamin deficiency. It has been hypothesized that these dogs have a primary methylmalonic aciduria. Of note, hypocobalaminemia is also associated with an increased prevalence of EPI in Border Collies.

**Beagle**

Hereditary cobalamin malabsorption is reported in Beagle dogs, and 2 Beagles with selective cobalamin malabsorption developed degenerative liver disease. The hepatopathies seen in these dogs might be associated with the chronic hyperhomocysteinemia which was demonstrated to promote hepatic inflammation and fibrosis in an experimental study in rats. Degenerative hepatopathies are also well described in farm animals, especially in lambs and goats with decreased cobalt intake causing hypocobalaminemia, but this etiology has not been reported in dogs with hereditary cobalamin malabsorption.

Decreased phagocytic activity has been demonstrated in human patients with cobalamin deficiency. Cobalamin-deficient Beagle dogs are suspected to be immunosuppressed, supporting the development of complicating infections such as fungal hepatopathy or necrotizing pneumonia.

**Chinese Shar-Pei**

Chinese Shar-Peis have a high prevalence of cobalamin deficiency compared to other canine breeds. Even apparently healthy Chinese Shar-Peis have increased serum MMA concentrations compared to healthy dogs of other breeds, which led to the hypothesis that some healthy Chinese Shar-Peis have subclinical cobalamin deficiency. Cobalamin deficiency in Chinese Shar-Peis is also associated with hyperhomocysteinemia. Clinical signs of affected dogs reflect primarily an involvement of the GI tract with chronic signs of GI disease such as diarrhea, vomiting, and weight loss. Classical signs of cobalamin deficiency such as hyperammonemia, hypoglycemia, and seizures are typically lacking in these dogs.

Hypocobalaminemia in Chinese Shar-Peis is not associated with other common diseases in this breed such as cutaneous mucinosis or Shar-Pei fever. However, evaluation of several biomarkers of inflammation suggests the existence of an inflammatory phenotype in both hypocobalaminemic and normocobalaminemic Chinese Shar-Peis.

This might reflect compromised GI health in affected dogs, with the result of a low-grade inflammation and malabsorption of vitamins such as cobalamin.

**Komondor**

A recent study reported that selective cobalamin malabsorption is also inherited via an autosomal recessive trait in Komondor dogs, an old Hungarian herding dog breed.

### 4.2.3 Genetic causes of selective cobalamin malabsorption

Each of the 2 subunits of the cubam receptor complex (ie, AMN and CUBN) depends on the normal structure of the other part of the receptor for epithelial brush border expression and function. Several (close to 400) AMN and CUBN mutations occur in people with IGS. In dogs, only 2 AMN mutations and 4 CUBN mutations have been identified to date.

Cubam expression is disrupted by 2 independent mutations in the AMN gene in Australian Shepherd dogs and Giant Schnauzers. A CUBN mutation causes IGS in Border Collies. A CUBN mutation is also responsible for canine IGS in the Beagle breed. The CUBN mutation in juvenile Beagle dogs causes more severe cobalamin malabsorption than a different CUBN defect in Border Collies and the former condition to resemble more closely IGS caused by AMN mutations in Giant Schnauzers and Australian Shepherd dogs. A residual CUBN expression, which does not exist in affected Beagle dogs, might explain why the diagnosis in some Border Collies can be delayed compared to affected dogs of other breeds. Furthermore, in a study including 200 randomly selected Border Collies, the frequency of dogs being heterozygous for the CUBN mutation was relatively low at 6.2%, whereas increased carrier frequency has been noted in Beagles, but the disease occurrence might be geographically dependent. In Komondor dogs, a CUBN splice-site variant causes cobalamin deficiency. Genetic tests have become commercially available and allow for a diagnosis prior to the clinical manifestation of the condition and also the detection of asymptomatic carriers to guide breeding decisions.

### 4.3 Gastrointestinal diseases

#### 4.3.1 Exocrine pancreatic insufficiency

Cobalamin deficiency is common in dogs with EPI. A study showed 82% of dogs with EPI have decreased serum cobalamin concentrations, and 36% of these dogs had severe hypocobalaminemia (defined as a serum cobalamin concentration of <100 ng/L in this study).
breed predisposition for EPI exists in German Shepherd Dogs, Rough Coated Collies, Chow-Chows, Cavalier King Charles Spaniels, and West Highland White Terriers, with German Shepherd Dogs representing about 60% of all cases of EPI.66 Pancreatic acinar atrophy is also an inherited disorder in the Eurasian breed.66

Exocrine pancreatic insufficiency is characterized by an inadequate production of digestive enzymes from pancreatic acinar cells, leading to the typical clinical signs of weight loss in the face of polyphagia and increased fecal volume.97,98 Failure to absorb cobalamin in dogs with EPI might be caused by 4 postulated or hypothetical mechanisms: pancreatic secretion of IF is reduced or absent, digestive enzymes are lacking causing an impaired release of cobalamin from haptocorrin and thus no binding of cobalamin to IF, secondary SI dysbiosis compromising the endogenous production of cobalamin, and the intestinal mucosa might also be compromised by the presence of toxic metabolites due to SI dysbiosis.9,99-101 However, in people cobalamin assimilation does not improve with antibiotic treatment,102 and there is no data that demonstrate a benefit of probiotics (eg, Enterococcus faecium SF68103) or prebiotics.

Because the exocrine pancreas is the major site of IF synthesis in dogs, cobalamin supplementation is often necessary in these dogs. However, cobalamin deficiency in some cases is not corrected by enzyme replacement alone likely because IF is not consistently a component of the exogenous enzyme mixture.99 Treatment with bovine pancreatic enzyme extract is also not sufficient to restore cobalamin absorption in dogs with EPI, because IF appears to be species-specific. The fact that serum cobalamin concentrations <100 ng/L are a negative prognostic factor64 underlines the importance to adequately supplement dogs with EPI, but only 4 of 135 (3%) hypocobalaminemic dogs with EPI were given supplemental cobalamin in that study.66 Another recent study revealed a prevalence of hypocobalaminemia (serum cobalamin concentration <350 ng/L) of 55% in dogs with EPI.104 Hypocobalaminemia was also shown to be a negative prognostic factor in that study, and 112 of 116 dogs (82%) received cobalamin supplementation.104

4.3.2 | Chronic inflammatory enteropathies

Chronic inflammatory enteropathies (CIE), further classified based on the response to treatment as either food-responsive enteropathy, antibiotic-responsive enteropathy, immunosuppressant-responsive enteropathy (IRE), or nonresponsive enteropathy (NRE), are characterized by chronic persistent or recurrent clinical signs of GI disease (such as vomiting, diarrhea, weight loss, or a combination of those) for longer than 3 weeks and are diagnosed retrospectively based on the response to treatment.65,71

It has been postulated that chronic mucosal disease affecting the ileum reduces the epithelial expression or function of the cubam receptor leading to a reduced mucosal uptake of cobalamin. However, currently there are no studies that have investigated the expression levels of the ileal cobalamin-IF-receptor in dogs with chronic enteropathies. In addition, cobalamin has been hypothesized to be decreased in dogs with CIE because of secondary SI dysbiosis. Once the body stores of cobalamin are depleted, cobalamin deficiency can occur.105 The half-life of cobalamin in healthy dogs is approximately 6-16 weeks.106 It is assumed that this half-life is decreased in dogs with CIE as a result of a reduced cobalamin absorption in the face of normal biliary excretion and enterohepatic circulation.49

Reported prevalences of hypocobalaminemia in dogs with CIE ranged from 19% to 38%,49,65,107-110 and similar findings have been reported in cats.111 Dogs with suboptimal serum cobalamin status might not respond to treatment of the primary disease process unless given supplemental cobalamin, because cobalamin is essential for many cell functions and mucosal regeneration, and a deficiency can contribute to mucosal inflammatory infiltration and villous atrophy.72,105

Correlation of hypocobalaminemia with histopathologic findings

Histological lesions in dogs with CIE are often multifocally distributed, and different degrees of disease severity might be found among the different segments of the intestinal tract and also among different regions within the same segment (Dossin O, Tessyedere JF, Concordet D. Is duodenal mucosa representative of other small intestinal parts in inflammatory bowel disease affected dogs? J Vet Intern Med. 2007;21:613 [abstract]).112,114 Because histological lesions of CIE might be found in the ileum in the face of a normal duodenal mucosa, ileal biopsies should be routinely collected in addition to duodenal biopsies in all dogs with chronic signs of GI disease undergoing GI endoscopy.112,114

Hypocobalaminemia correlates with an increased number of intraepithelial lymphocytes in the ileal mucosa,114 presenting evidence of an association between ileal mucosal inflammatory changes and hypocobalaminemia in dogs with CIE. However, the expression of the cobalamin-receptor in dogs with CIE has not been evaluated.

Correlation of hypocobalaminemia with outcome in dogs

Several factors have been evaluated for their potential to predict outcome in dogs with CIE.65 In addition to the presence of severe mucosal lesions in the duodenum and hypoalbuminemia (serum albumin concentration of <20 g/L), hypocobalaminemia (defined as a serum cobalamin concentration of <200 ng/L in this study) at the time of diagnosis might predict refractoriness to treatment and was strongly correlated with a negative outcome despite supplementation of cobalamin for 6 weeks.65 However, despite that hypocobalaminemia is a negative prognostic factor, adequate supplementation of cobalamin appears to be essential for the success of treatment. Thus, further studies need to investigate if early initiation of cobalamin supplementation is associated with a better outcome in dogs with CIE. Hypocobalaminemia also correlates with hypoalbuminemia in dogs with CIE.65,108,109

Protein-losing enteropathy

Protein-losing enteropathy is a syndrome associated with an abnormal loss of albumin into the intestinal lumen. Common causes for PLE are
altered lymphatic drainage or increased mucosal permeability. A predisposition for primary intestinal lymphangiectasia exists in Rottweilers, Yorkshire Terriers, Chinese Shar-Peis, Maltese, Norwegian Lundehunds, Basenjis, Soft Coated Wheaten Terriers, and German Shepherd Dogs. Secondary intestinal lymphangiectasia is associated with mucosal inflammation in IRE/NRE, intestinal neoplasia, or infectious diseases (e.g., GI histoplasmosis) in dogs. Prevalences of hypocobalaminemia range from 43%-75% in dogs with non-neoplastic, noninfectious causes of PLE. Hypocobalaminemia was also associated with decreased serum alpha1-proteinase inhibitor concentrations (presumably due to PLE) in Yorkshire Terriers.

Serum cobalamin concentrations should be evaluated in all dogs with PLE and, if needed, supplemental cobalamin be started early.

4.3.3 | Alimentary lymphoma

Sixteen percent of dogs with multicentric lymphoma have hypocobalaminemia, and this finding is associated with a poor outcome. A higher rate of hypocobalaminemia (40% and 71%) is seen in dogs with low-grade (lymphocytic) GI lymphoma. It is presumed that the hypocobalaminemia in dogs with lymphoma is a consequence of the ileal infiltration with neoplastic lymphocytes hypothesetically resulting in a disruption of the receptor-mediated GI uptake of cobalamin.

4.3.4 | Small intestinal dysbiosis

Small intestinal (SI) dysbiosis is defined as an altered composition, richness, or both of the intestinal microbiota. Competition between bacteria and host cells for essential nutrients such as cobalamin can lead to malnutrition. Bacteroides spp. are the principle competitors for cobalamin with the host because of the ability to utilize cobalamin-IF complexes, in contrast to other bacteria that can only bind free cobalamin. If these folate-producing bacteria localize to the proximal intestine, an increased amount of folate of bacterial origin can be absorbed by the host resulting in increased serum folate concentrations. Hence, hypocobalaminemia with concurrent hyperfolatemia might suggest the presence of SI dysbiosis. However, there are currently no studies using culture-independent techniques that provide microbiological or ecological evidence of SI dysbiosis associated with systemic hypocobalaminemia or hyperfolatemia. The definitive diagnosis of SI dysbiosis remains challenging, and the diagnostic constellation of hypocobalaminemia with concurrent hyperfolatemia should not be used as a justification for antibiotic administration.

5 | TREATMENT

Cobalamin should be supplemented whenever serum cobalamin concentration is subnormal. There is a 12% probability that CIE dogs with low-normal serum cobalamin concentration (ie, less than approximately 400 ng/L) might also benefit from supplementation. Cyanocobalamin has traditionally been used for supplementation, as it is widely available and inexpensive. The possibility of normocobalaminemia being restored in hypocobalaminemic dogs with CIE when treating the underlying disease without supplementing cobalamin has not been demonstrated.

In dogs with CIE and suboptimal cobalamin status, cobalamin is recommended to be given at a dose of 50 μg/kg SC every 7 days or 50 μg/kg PO q24h. Current consensus is that over-supplementation with cobalamin or cobalamin toxicity does not occur. While this is a reasonable assumption based on theoretical considerations, there are no data available in companion animals to support this hypothesis. In people, chronic oversupplementation with cobalamin might increase the risk for lung cancer in smokers. In dogs with IGS, dosing intervals are highly variable with cobalamin injections being done weekly, every other week, every 4 weeks, or bimonthly. In 1 case that was supplemented every 4-5 months, clinical signs and methylmalonic aciduria returned. After starting cobalamin supplementation, appetite and well-being of dogs with IGS can return to normal within 12 to 48 hours and weight gain will follow over days to weeks. Normalization of hematological abnormalities can take up to 14 days. Urinary MMA excretion as well as the serum MMA concentration can be expected to normalize (ie, decrease to within RI) within a week of initiating cobalamin supplementation. However, proteinuria in dogs with selective cobalamin malabsorption will persist lifelong due to abnormal renal tubular cubam function that is not corrected by cobalamin supplementation. In people with IGS, tubular proteinuria does not adversely affect renal function, and long-term follow-up of affected human patients (up to 50 years) suggests that renal prognosis is excellent.

Dogs with selective cobalamin malabsorption—if left untreated—will die as a result of metabolic derangements and immunodeficiency. There is limited evidence-based information about the optimum route, dose, and dosing interval of cobalamin supplementation in dogs available. Currently either parenteral or oral cobalamin supplementation is recommended:

5.1 | Parenteral cobalamin supplementation

5.1.1 | Protocol

Initially, weekly SC injections of 50 μg/kg SC cyanocobalamin (250-1500 μg depending on the size of the dog; see Table S2) over a period of 6 weeks, then an additional dose 1 month later, followed by measurement of serum cobalamin concentration 1 month after the last dose.

5.1.2 | Monitoring

If the underlying disease process has resolved and cobalamin body stores have been restored, serum cobalamin concentration should be above the RI at the time of retesting. If serum cobalamin concentration is still within RI (ie, supranormal serum cobalamin concentrations have not been achieved), cobalamin supplementation was traditionally
recommended to be continued every 2-4 weeks. More than 90% of dogs with a suboptimal serum cobalamin status achieve hypocobalaminemia within 4 weeks of parenteral cobalamin supplementation, but serum cobalamin concentrations decreased within the RI towards the 12-week mark of cobalamin supplementation in the majority of these dogs.28 In some dogs, serum cobalamin concentrations are not adequate with cyanocobalamin supplementation, and hydroxocobalamin might be more effective in these dogs (Steiner JM, personal communication). However, monitoring serum MMA concentrations alone or in combination with serum cobalamin concentrations might be a more appropriate way to reevaluate the canine cobalamin status after treatment.59

A study investigating the effect of injectable hydroxocobalamin for the treatment of Beagle dogs with IGS showed a dose of 1 mg hydroxocobalamin administered IM to be adequate for maintaining a normal clinical status and normal urine MMA concentrations for up to 2 months.59 Hydroxocobalamin is considered the treatment of choice for children with IGS88,133,134 and other types of hereditary cobalamin deficiency.135,136 It is likely more effective than cyanocobalamin because this compound presents the natural form of cobalamin.137 In addition, IM injections of hydroxocobalamin appear to cause less pain than cyanocobalamin.134

5.2 | Oral cobalamin supplementation

5.2.1 | Protocol

Cobalamin (50 μg/kg PO) is administered once daily (250-1000 μg in dogs, depending on the size of the dog; see Table S3) over a period of 12 weeks,33 followed by a recheck of serum cobalamin concentration after discontinuation of supplementation. Dogs were rechecked the day after the last PO cobalamin dose in this study,33 but the authors typically recheck serum cobalamin concentration 1 week after the last cobalamin tablet.

5.2.2 | Monitoring

Several studies in human patients with hypocobalaminemia suggest that supplementation with oral cobalamin might be as effective as parenteral administration.138-140 A study that included 51 dogs showed that serum cobalamin concentrations increased significantly and normocobalaminemia was achieved in all hypocobalaminemic dogs with chronic enteropathy after daily oral cobalamin supplementation for at least 3 weeks (20-202 days).141 However, similar to this study, another investigation by the same research group showed that supranormal serum cobalamin concentrations were achieved in only about half of the dogs. The dogs in this study reached normal serum cobalamin concentrations within 4 weeks of receiving PO cobalamin, but a hypercobalaminemic state was reached after 12 weeks of PO cobalamin supplementation in about two thirds of these dogs.28 In addition, other recent studies suggest that daily PO cobalamin supplementation is effective to normalize the serum cobalamin status in dogs with CIE and also to maintain normal cobalamin status in dogs with hereditary cobalamin malabsorption that had previously been supplemented with parenteral hydroxocobalamin.28,47 Thus, oral cobalamin supplementation is a simple, noninvasive, and pain-free alternative to weekly SC injections of either cyanocobalamin or hydroxocobalamin.28,33 An alternative pathway of intestinal cobalamin absorption beyond receptor-mediated transport in the ileum is a possible explanation why oral cobalamin supplementation might be effective in spite of a defective receptor-mediated uptake into enterocytes. This has also been reported in people.51 However, expression levels of the ileal cobalamin-IF receptor in dogs with chronic enteropathies have not been investigated.

ACKNOWLEDGMENTS

Parts of this manuscript will be reproduced in Stefanie Kather’s doctoral thesis, which is generously supported by a research stipend conferred by the Jutta-and-Georg-Bruns foundation. The authors acknowledge support from the German Research Foundation (DFG) and Leipzig University within the program of Open Access Publishing as well as from the Biomaging Core Facility at the College of Veterinary Medicine, University of Leipzig, Germany.

CONFLICT OF INTEREST DECLARATION

Romy Heilmann has received speaker honoraria from Dechra company for presentations at continuing education meetings. Dechra has an oral cyanocobalamin formulation commercially available.

OFF-LABEL ANTIMICROBIAL DECLARATION

Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION

Authors declare no IACUC or other approval was needed.

HUMAN ETHICS APPROVAL DECLARATION

Authors declare human ethics approval was not needed for this study.

ORCID

Stefanie Kather https://orcid.org/0000-0001-5519-9107
Romy M. Heilmann https://orcid.org/0000-0003-3485-5157

REFERENCES

1. Fyfe JC, Jezky PF, Giger U, Patterson DF. Inherited selective malabsorption of vitamin B12 in Giant Schnauzers. J Am Anim Hosp Assoc. 1989;25:533-539.
2. Hand M, Thatcher C, Remillard LR. Klinische Diätetik für Kleintiere. 4th ed. Hanover, Germany: Schlutersche GmbH & Co. KG; 2010: 60-72.

3. Semp PG. Vegan Nutrition of Dogs and Cats [dissertation]. Vienna, Austria: Veterinary Medical University (VetMedUni) of Vienna; 2014.

4. Davenport DJ, Ching RJW, Hunt JH, Bruyette DS, Gross KL. The effect of dietary levels of folate and cobalamin on the serum concentration of folate and cobalamin in the dog. J Nutr. 1994;124:2559-2562.

5. National Research Council (NRC). Nutrient requirements of dogs and cats. Washington, DC: National Academic Press; 2006.

6. Lutz S, Sewell AC, Bigler B, Riond B, Reusch CE, Kook PH. Serum cobalamin, urine methylmalonic acid, and plasma total homocysteine concentrations in Border Collies and dogs of other breeds. Am J Vet Res. 2012;73(8):1194-1199.

7. Qureshi AA, Rosenblatt DS, Cooper BA. Inherited disorders of cobalamin metabolism. Crit Rev Oncol Hematol. 1994;17(2):133-151.

8. Marcoullis G, Rothenberg SP. Intrinsic factor-mediated intestinal absorption of cobalamin in the dog. Am J Physiol. 1981;241(4):G294-G299.

9. Batt RM, Horadagoda NU. Gastric and pancreatic intrinsic factor-mediated absorption of cobalamin in the dog. Am J Physiol. 1989;257(3):344-349.

10. Fyfe JC, Madsen M, Højrup P, et al. The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubulin and amnionless. Blood. 2004;103(5):1573-1579.

11. Berlin H, Berlin R, Brante G. Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. Acta Med Scand. 1986;184(4):247-258.

12. Hall CA. Transcobalamin I and II as natural transport proteins of vita- min B12. J Clin Invest. 1975;56(4):1125-1131.

13. Quadros EV, Sequeira JM. Cellular uptake of cobalamin: transcobalamin and the TCblR/CD320 receptor. Biochimie. 2013;95(5):1008-1018.

14. Rappazzo ME, Hall CA. Cyanocobalamin transport proteins in canine plasma. Am J Physiol. 1972;222(1):202-206.

15. Willigan DA, Cronkite EP, Meyer LM, Noto SL. Biliary excretion of Co60 labeled vitamin B12 in dogs. Proc Soc Exp Biol Med. 1958;99(1):81-84.

16. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnor- malities in cobalamin (vitamin B12) and folate deficiency. FASEB J. 1993;7(14):1344-1353.

17. Fordyce HH, Callan MB, Giger U. Persistent cobalamin deficiency causing failure to thrive in a juvenile beagle. J Small Anim Pract. 2000;41(9):407-410.

18. Battersby IA, Giger U, Hall EJ. Hyperammonaemic encephalopathy secondary to selective cobalamin deficiency in a juvenile Border col- lie. J Small Anim Pract. 2005;46(7):339-344.

19. Gold AJ, Scott MA, Fyfe JC. Failure to thrive and life-threatening complications due to inherited selective cobalamin malabsorption effectively managed in a juvenile Australian shepherd dog. Can Vet J. 2015;56(10):1029-1034.

20. McLauchlan G, McLauchlin A, Sewell AC, Bell R. Methylmalonic aciduria secondary to selective cobalamin malabsorption in a York- shire Terrier. J Am Anim Hosp Assoc. 2015;51(4):285-288.

21. Ruaux CG, Steiner JM, Williams DA. Metabolism of amino acids in cats with severe cobalamin deficiency. Am J Vet Res. 2001;62(12): 1852-1858.

22. Marisco PD, Ribeiro MC, Bonini JS, et al. Ammonia potentiates methylmalonic acid-induced convulsions and TxBARs production. Exp Neurol. 2003;182(2):455-460.

23. Moestrup SK, Birn H, Fischer PB, et al. Megalin-mediated endocryo- sis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B12 homeostasis. Proc Natl Acad Sci. 1996;93(16):8612-8617.

24. Birn H, Willnow TE, Nielsen R, et al. Megalin is essential for renal proximal tubule reabsorption and accumulation of transcobalamin- B12. Am J Physiol Renal Physiol. 2002;282(3):408-416.

25. He Q, Madsen M, Kilkenney A, et al. Amnionless function is required for cubilin brush-border expression and intrinsic factor-cobalamin (vitamin B12) absorption in vivo. Blood. 2003;106(4):1447-1453.

26. Berghoff N, Suchodolski JS, Steiner JM. Association between serum cobalamin and methylmalonic acid concentrations in dogs. Vet J. 2012;191(3):306-311.

27. Grützer N, Heilmann RM, Supka KC, et al. Serum homocysteine and methylmalonic acid concentrations in Chinese Shar-Pei dogs with cobalamin deficiency. Vet J. 2013;197(2):420-426.

28. Toresson L, Steiner JM, Razdan P, et al. Comparison of efficacy of oral and parenteral cobalamin supplementation in normalising low cobalamin concentrations in dogs: a randomised controlled study. Vet J. 2018;232:27-32.

29. McLeish SA, Burt K, Papasouliotis K. Analytical quality assessment and method comparison of immunoassays for the measurement of serum cobalamin and folate in dogs and cats. J Vet Diagn Invest. 2019;31(2):164-174.

30. D可疑 O. Laboratory tests for diagnosis of gastrointestinal and pan- creatic diseases. Top Companion Anim Med. 2011;26(2):86-97.

31. Ruaux CG. Cobalamin in companion animals: diagnostic marker, defi- ciency states and therapeutic implications. Vet J. 2013;196(2): 145-152.

32. Kempf J, Melliger RH, Reusch CE, Kook PH. Effects of storage con- ditions and duration on cobalamin concentration in serum samples from cats and dogs. J Am Vet Med Assoc. 2018;152(11):1368-1371.

33. Toresson L, Steiner JM, Spodsborg E, et al. Effects of oral versus parenteral cobalamin supplementation on methylmalonic acid and homocysteine concentrations in dogs with chronic enteropathies and low cobalamin concentrations. Vet J. 2019;243:8-14.

34. Duthie SJ, Horgan G, de Roos B, et al. Blood folate status and expression of proteins involved in immune function, inflammation, and coagulation: biochemical and proteomic changes in the plasma of humans in response to long-term synthetic folate acid supplementa- tion. J Proteome Res. 2010;9(4):1491-1495.

35. Cullen CE, Carter GT, Weiss MD, Grant PA, Saperstein DS. Hypohomocysteinemia: a potentially treatable cause of peripheral neuropathology? Phys Med Rehabil Clin N Am. 2012;23(2):59-65.

36. Lippi G, Plebani M. Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here? Clin Chem Lab Med. 2012;50(12):2075-2080.

37. Stanger O, Herrmann W, Pietrizik K, et al. DACH-Liga homocysteine (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid an B-vitamins in cardiovascular and thrombotic diseases: guidelines and recom- mendations. Clin Chem Lab Med. 2003;41(11):1392-1403.

38. Heilmann RM, Grützer N, Iazbik MC, et al. Hyperhomocysteinemia in Greyhounds and its association with hypofolatemia and other clin- icopathologic variables. J Vet Intern Med. 2017;31(1):109-116.

39. Herrmann W, Obeid R. Cobalamin deficiency. Subcell Biochem. 2012; 56:301-322.

40. Amin HK, El-Sayed MI, Leheta OF. Homocysteine as a predicti- ve biomarker in early diagnosis of renal failure susceptibility and prog- nostic diagnosis for end stages renal disease. Ren Fail. 2016;38(8): 1267-1275.

41. Gołyński M, Lutrnicki K, Krumrych W, et al. Relationship between total homocysteine, folic acid, and thyroid hormones in hypothyroid dogs. J Vet Intern Med. 2017;31(5):1403-1405.

42. Folstein M, Liu T, Peter I, et al. The homocysteine hypothesis of depression. Am J Psychiatry. 2007;164(6):861-867.
43. Matté C, Stefanello FM, Mackedanz V, et al. Homocysteine induces oxidative stress, inflammatory infiltration, fibrosis and reduces glycogen/glycoprotein content in liver of rats. *Int J Dev Neurosci*. 2009;27(4):337-344.

44. Rossi S, Rossi G, Giordano A, Paltrinieri S. Homocysteine measurement by an enzymatic method and potential role of homocysteine as a biomarker in dogs. *J Vet Diagn Invest*. 2008;20(5):644-649.

45. Grützner N, Suchodolski JS, Steiner JM. Relationship between cobalamin-dependent metabolites and both serum albumin and alpha2-proteinase inhibitor concentrations in hypocobalaminemic dogs of 7 different breeds. *Vet Clin Pathol*. 2014;43(4):561-566.

46. Willems HP, Bos GM, Gerrits WB, den Heijer M, Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. *Clin Chem*. 1998;44(2):342-345.

47. Kook PH, Hersberger M. Daily oral cyanocobalamin supplementation in Beagles with hereditary cobalamin malabsorption (Imerslund-Gräsbeck syndrome) maintains normal clinical and cellular cobalamin status. *J Vet Intern Med*. 2019;33(2):751-757.

48. Moelby L, Rasmussen K, Rasmussen HH. Serum methylmalonic acid —

49. Suchodolski JS. Diagnosis and interpretation of intestinal dysbiosis in dogs and cats. *Vet J*. 2016;215:30-37.

50. Sewell AC, Herwig J, Böhles H. A case of familial "benign" methylmalonic aciduria? *J Inherit Metab Dis*. 1996;19(5):696-697.

51. Hörster F, Baumgartner MR, Viardot C, et al. Long-term outcome in dogs and cats with cobalamin and methylmalonic acid concentrations in dogs with chronic gastrointestinal disease. *Am J Vet Res*. 2013;74(1):84-89.

52. Suchodolski JS. Homocysteine induces intestinal dysbiosis in dogs and cats. *Vet J*. 2016;215:30-37.

53. Fedosov SN. Physiological and molecular aspects of cobalamin transport. *Subcell Biochem*. 2012;56:347-367.

54. Kook PH, Reusch CE, Hersberger M. Prospective long-term evaluation of serum cobalamin concentrations in dogs of 164 dog breeds. *Clin Chem*. 2014;60:289-298.

55. Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal dysbiosis secondary to proton-pump inhibitor use. *Digestion*. 2018;97(2):195-204.

56. Zarrinpar A, Chaix A, Xu ZZ, et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. *Nat Commun*. 2018;9(1):2872.

57. Fedosov SN. Physiological and molecular aspects of cobalamin transport. *Subcell Biochem*. 2012;56:347-367.

58. Kook PH, Reusch CE, Hersberger M. Prospective long-term evaluation of parenteral hydroxocobalamin supplementation in juvenile beagles with selective intestinal cobalamin malabsorption (Imerslund-Gräsbeck syndrome). *J Vet Intern Med*. 2018;32:1033-1040.

59. Andrés E, Serraj K, Zhu J, Vermorken AJ. The pathophysiology of elevated vitamin B12 in clinical practice. *QJM*. 2013;106(6):505-515.

60. Arendt JF, Nexo E. Unexpected high plasma cobalamin: proposal for a diagnostic strategy. *Clin Chem Lab Med*. 2013;51(3):489-496.

61. Brah S, Chiche L, Mancini J, Meunier B, Arlet JB. Characteristics of patients admitted to internal medicine departments with high serum cobalamin levels: results from a prospective cohort study. *Eur J Intern Med*. 2014;25(5):e57-e58.

62. Trehy MR, German AJ, Silvestrini P, Serrano G, Batchelor DJ. Hypocobalaminemia is associated with hepatic and neoplastic disease in cats: a cross sectional study. *BMC Vet Res*. 2014;10:175.

63. German AJ, Day MJ, Ruaux CG, Steiner JM, Williams DA, Hall EJ. Comparison of direct and indirect tests for small intestinal bacterial overgrowth and antibiotic-responsive diarrhea in dogs. *J Vet Intern Med*. 2003;17(1):33-43.

64. Alpersch K, Wieland B, Grüne A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. *J Vet Intern Med*. 2007;21(4):700-708.

65. Batchelor DJ, Noble PJ, Taylor RH, Cripps PJ, German AJ. Prognostic factors in canine exocrine pancreatic insufficiency: prolonged survival is likely if clinical remission is achieved. *J Vet Intern Med*. 2007;21(1):54-60.

66. Suchodolski JS. Alterations in the small intestinal microflora (small intestinal bacterial overgrowth). In: Steiner JM, eds. *Small Animal Gastroenterology*. Hannover, Germany: Schlütersche; 2007:202-207.

67. Cook AK, Wright ZM, Suchodolski JS, Brown MR, Steiner JM. Prevalence and prognostic impact of hypocobalaminemia in dogs with lymphoma. *J Am Med Assoc*. 2007;235(12):1437-1441.

68. Dossin O, Lavoué R. Protein-losing enteropathies in dogs. *Vet Clin North Am Small Anim Pract*. 2011;41(2):399-418.

69. Grützner N, Cranford SM, Norby B, Suchodolski JS, Steiner JM. Evaluation of serum cobalamin concentrations in dogs of 164 dog breeds (2006-2010). *J Vet Diagn Invest*. 2012;24(6):1105-1114.

70. Dandrieux JR. Inflammatory bowel disease versus chronic enteropathy in dogs: are they one and the same? *J Small Anim Pract*. 2016;57(11):589-599.

71. Weiss DJ. Congenital dyserthropoiesis. In: Weiss JD, Wardrop KJ, eds. *Schalm's Veterinary Hematology*. Vol. 6. Ames, Iowa: Wiley; 2010:196-197.

72. Arvanitakis C. Functional and morphological abnormalities of the small intestinal mucosa in pernicious anemia—a prospective study. *Acta Hepatogastroenterol*. 1978;25:313-318.

73. Frye JC, Giger U, Hall CA, et al. Inherited selective intestinal cobalamin malabsorption and cobalamin deficiency in dogs. *Pediatr Res*. 1991;29(1):24-31.

74. Morgan LW, McConnell J. Cobalamin deficiency associated with erythroblastic anemia and methylmalonic aciduria in a Border Collie. *J Am Anim Hosp Assoc*. 1999;35(5):392-395.

75. Lutz S, Sewell AC, Reusch CE, Kook PH. Clinical and laboratory findings in Border Collies with presumed hereditary juvenile cobalamin deficiency. *J Am Anim Hosp Assoc*. 2013;49(3):197-203.

76. Owczarek-Lipska M, Jagannathan V, Drögemüller C, et al. A frameshift mutation in the cubilin gene (CUBN) in Border Collies with Imerslund-Gräsbeck syndrome (selective cobalamin malabsorption). *PLoS One*. 2013;8(4):e61144.

77. Erles K, Mugford A, Barfield D, Leeb T, Kook PH. Systemic *Scedosporium prolificans* infection in an 11-month-old Border collie with cobalamin deficiency secondary to selective cobalamin malabsorption (canine Imerslund-Gräsbeck syndrome). *J Small Anim Pract*. 2018;59(4):253-256.

78. Grützner N, Bishop MA, Suchodolski JS, Steiner JM. Association Study of Cobalamin Deficiency in the Chinese Shar Pei. *J Hered*. 2010;101(2):211-217.

79. Bishop MA, Xenoulis PA, Berghoff N, Grützner N, Suchodolski JS, Steiner JM. Partial characterization of cobalamin deficiency in Chinese Shar Pei. *Vet J*. 2012;191(1):41-45.

80. Frye JC, Hemker SL, Venta PJ, Stebbing B, Giger U. Selective intestinal cobalamin malabsorption with proteinuria (Imerslund-Gräsbeck syndrome) in juvenile Beagles. *Vet J*. 2014;282:356-362.

81. Drögemüller M, Jagannathan V, Howard J, et al. A frameshift mutation in the cubilin gene (CUBN) in Beagles with Imerslund-Gräsbeck syndrome (selective cobalamin malabsorption). *Anim Genet*. 2014;45(1):148-150.

82. Kook PH, Drögemüller M, Leeb T, Howard J, Ruetten M. Degenerative liver disease in young Beagles with hereditary cobalamin...
malabsorption because of a mutation in the cubilin gene. J Vet Intern Med. 2014;28(2):666-671.

84. Dandrieux JR, Noble PJM, Halladay LJ, McLean L, German AJ. Canine breed predispositions for marked hypocobalaminemia or decreased folate concentration assessed by a laboratory survey. J Small Anim Pract. 2013;54(3):143-148.

85. Surfing K, Batchelor D, German A, Piviani M, Silvestrini P. Congenital cobalamin malabsorption (Imerslund-Gräsbeck syndrome) in two Beagles in the UK. Vet Rec Case Rep. 2015;3:e000201.

86. Shihvalan S, Srinath MV. Reversible skin hyperpigmentation in Imerslund-Gräsbeck syndrome. Indian Pediatr. 2015;50(10):973-974.

87. Fyfe JC. Hematology of selective intestinal cobalamin malabsorption. In: Weiss JD, Wardrop KJ, eds. Schalm’s Veterinary Hematology. Vol 2, S. Philadelphia, Pennsylvania: Wiley; 2000:695-770.

88. Gräsbeck R. Imerlsund-Gräsbeck syndrome (selective vitamin B12 malabsorption with proteinuria). Orphanet J Rare Dis. 2006;1:17.

89. Stanley E, Appleman E, Schlag A, Siegel A. Relationship between cobalamin and folate deficiencies and anemia in dogs. J Vet Intern Med. 2019;33(1):106-113.

90. Barron PM, Wouda RM. Congenital cobalamin deficiency in seven Beagle puppies. Austral Vet Pract. 2008;38:126-132.

91. Skacel PO, Chanarin I. Impaired chemiluminescence and bactericidal killing by neutrophils from patients with severe cobalamin deficiency. Br J Haematol. 1983;55(2):203-215.

92. Kook PH, Drögemüller M, Leeb HS, Ruetten M, Howard JJ. Hepatic fungal infection in a young beagle with unrecognised hereditary cobalamin deficiency (Imerslund-Gräsbeck syndrome). J Small Anim Pract. 2015;56(2):138-141.

93. Grützner N, Heilmann RM, Cranford SM, Holzenburg A, Peterson PB, Willard MD. Protein-losing enteropathy in Yorkshire Terriers. Revue de méd vét. 2013;109(4):390-396.

94. Procoli F, Motsküla PF, Keyte SV, Priestnall S, Allenspach K. Comparison of histopathologic findings in duodenal and ileal endoscopic biopsies in dogs with chronic small intestinal enteropathies. J Vet Intern Med. 2010;24(1):80-83.

95. Kleinschmidt S, Mennes F, Nolte I, Hewicker-Trautwein M. Retrospective study on the diagnostic value of full-thickness biopsies from the stomach and intestine of dogs with chronic gastrointestinal disease symptoms. Vet Pathol. 2006;43(6):1000-1003.

96. Casamian-Sorrosal D, Willard MD, Murray JK, Hall EJ, Taylor SS, Day MJ. Comparison of histopathologic findings in biopsies from the duodenum and ileum of dogs with enteropathy. J Vet Intern Med. 2010;24(1):80-83.

97. Procholi F, Motsküla PF, Keyte SV, Priestnall S, Allenspach K. Comparison of histopathologic findings in duodenal and ileal endoscopic biopsies in dogs with chronic small intestinal enteropathies. J Vet Intern Med. 2013;27(2):268-274.

98. Peterson PB, Willard MD. Protein-losing enteropathies. Vet Clin North Am Small Anim Pract. 2003;33(5):1061-1082.

99. Pettersson CA, Broman L, Broman L. MacLachlan NJ, Breitschwerdt EB, Chambers JM, Argenzio RA, Buyscher EV. Gastroenteritis of Basenji dogs. Vet Pathol. 1988;25(1):36-41.

100. Littmann MP, Dambach DM, Vaden SL, Giger U. Familial protein-losing enteropathy and protein-losing nephropathy in Soft Coated Wheaten terriers: 222 cases (1983-1997). J Vet Intern Med. 2000;14(1):60-68.

101. Berghoff N, Ruaux CG, Steiner JM, Williams DA. Gastroenteropathy in Norwegian Lundehunds. Compend Contin Educ Vet. 2007;29(8):456-465.

102. Dijkstra M, Kraus JS, Bosie JT, Den Hertog E. Protein-losing enteropathy in Rottweilers. Tijdschr Diergeneeskd. 2010;135(10):406-412.

103. Simmerson SM, Armstrong PJ, Wünschmann A, Jeness CR, Crews LJ, Washabau RJ. Clinical features, intestinal histopathology, and outcome in protein-losing enteropathy in Yorkshire Terrier dogs. J Vet Intern Med. 2014;28(2):331-337.

104. Boa D, Lecoindre A, Poujade A, et al. Protein losing enteropathy in Yorkshire Terriers—retrospective study in 31 dogs. Revue de med vét. 2016;167(1-2):2-9.

105. Wennober SA, Priestnall SL, Webb CB. Histopathologic characteristics of intestinal biopsy samples from dogs with chronic inflammatory enteropathy with and without hypoalbuminemia. J Vet Intern Med. 2017;31(2):371-376.

106. Rudinsky AJ, Howard JP, Bishop MA, Sherding RG, Parker VJ, Gilor C. Dietary management of presumptive protein-losing enteropathy in Yorkshire terriers. J Vet Intern Med. 2018;58(2):103-108.
124. Equilino M, Théodoloz V, Gorgas D, et al. Evaluation of serum biochemical marker concentrations and survival time in dogs with protein-losing enteropathy. J Am Vet Med Assoc. 2015;246(1):91-99.

125. Grützner N, Heilmann RM, Bridges CS, Suchodolski JS, Steiner JM. Serum concentration of canine alpha1-proteinase inhibitor in cobalamin-deficient Yorkshire Terrier dogs. J Vet Diagn Investig. 2013;25(3):376-385.

126. Couto KM, Moore PF, Zwingenberger AL, Willcox JL, Skorupski KA. Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Vet Comp Oncol. 2018;16(3):147-153.

128. Abrams GD. Microbial effects on mucosal structure and function. Am J Clin Nutr. 1977;30(11):1880-1886.

129. European Food and Safety Authority (EFSA). Scientific opinion on dietary reference values for cobalamin (vitamin B12). EFSA J. 2015;13(7):4150.

130. Brasky TM, White E, Chen CL. Long-term, supplemental, one-carbon metabolism-related vitamin B use in relation to lung cancer risk in the vitamins and lifestyle (VITAL) cohort. J Clin Oncol. 2017;35(30):3440-3448.

131. Verroust PJ. Pathophysiology of cubilin: of rats, dogs and men. Nephrol Dial Transplant. 2002;17(9):55-56.

132. Broch H, Imerlund O, Monn E, Hovig T, Seip M. Imerlund-Gräsbeck anemia. A long-term follow-up study. Acta Paediatr Scand. 1984;73(2):248-253.

133. Fowler B, Leonard JV, Baungartner MR. Causes of and diagnostic approach to methylmalonic acidurias. J Inherit Metab Dis. 2008;31(3):350-360.

134. Gräsbeck R. Involuntary movements during vitamin B12 treatment: was cyanocobalamin perhaps responsible? J Child Neurol. 2010;25(6):794-795.

135. Anderson HC, Shapira E. Biochemical and clinical response to hydroxocobalamin versus cyanocobalamin treatment in patients with methylmalonic academia and homocysteinuria (cblC). J Pediatr. 1998;132(1):121-124.

136. Zwickler T, Lindner M, Aydin HI, et al. Diagnostic work-up and management of patients with isolated methylmalonic acidurias in European metabolic centres. J Inherit Metab Dis. 2008;31(3):361-367.

137. Farquharson J, Adam JF. The forms of vitamin B12 in foods. Br J Nutr. 1976;36(1):127-136.

138. Kuzminski AM, del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1999;92(4):1191-1198.

139. Kim HI, Hyung WJ, Song KJ, Choi SH, Kim CB, Noh SH. Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. Ann Surg Oncol. 2011;18(13):3711-3717.

140. Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Lio TH. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2018;3:CD004655.

141. Toresson L, Steiner JM, Suchodolski JS, Spillmann T. Oral cobalamin supplementation in dogs with chronic enteropathies and hypocobalaminemia. J Vet Intern Med. 2016;30(1):101-107.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Kather S, Grützner N, Kook PH, Dengler F, Heilmann RM. Review of cobalamin status and disorders of cobalamin metabolism in dogs. J Vet Intern Med. 2020;34:13-28. https://doi.org/10.1111/jvim.15638